Hims & Hers Health (NYSE:HIMS) Insider Irene Becklund Sells 7,573 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) insider Irene Becklund sold 7,573 shares of Hims & Hers Health stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $30.25, for a total transaction of $229,083.25. Following the transaction, the insider owned 11,280 shares in the company, valued at approximately $341,220. This trade represents a 40.17% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Irene Becklund also recently made the following trade(s):

• On Wednesday, June 17th, Irene Becklund sold 4,490 shares of Hims & Hers Health stock. The stock was sold at an average price of $31.50, for a total value of $141,435.00.

Hims & Hers Health Price Performance

Shares of Hims & Hers Health stock traded up $0.50 during trading hours on Wednesday, hitting $31.97. The company’s stock had a trading volume of 23,080,110 shares, compared to its average volume of 30,466,682. The business has a 50 day moving average price of $25.87 and a two-hundred day moving average price of $26.65. Hims & Hers Health, Inc. has a 12-month low of $13.74 and a 12-month high of $70.43. The company has a market cap of $7.40 billion, a PE ratio of -355.22, a PEG ratio of 56.60 and a beta of 2.37. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.56 and a current ratio of 1.69.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). The business had revenue of $608.10 million during the quarter, compared to the consensus estimate of $616.84 million. Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.The business’s revenue was up 3.8% on a year-over-year basis. During the same period last year, the company earned $0.20 EPS. Analysts expect that Hims & Hers Health, Inc. will post 0.04 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

HIMS has been the subject of a number of research analyst reports. Zacks Research cut shares of Hims & Hers Health from a “hold” rating to a “strong sell” rating in a research report on Monday, June 8th. BTIG Research restated a “neutral” rating on shares of Hims & Hers Health in a research report on Tuesday, May 12th. JPMorgan Chase & Co. cut their target price on shares of Hims & Hers Health from $35.00 to $33.00 and set an “overweight” rating for the company in a research note on Tuesday, May 12th. Needham & Company LLC lifted their price target on shares of Hims & Hers Health from $30.00 to $35.00 and gave the company a “buy” rating in a report on Tuesday, May 12th. Finally, Barclays reiterated an “overweight” rating and issued a $39.00 price target on shares of Hims & Hers Health in a research note on Wednesday. Four analysts have rated the stock with a Buy rating, ten have issued a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $29.37.

Institutional Investors Weigh In On Hims & Hers Health

Several large investors have recently bought and sold shares of HIMS. Flagship Harbor Advisors LLC purchased a new stake in Hims & Hers Health during the fourth quarter valued at $28,000. Binnacle Investments Inc purchased a new stake in Hims & Hers Health during the third quarter valued at $28,000. Bogart Wealth LLC raised its stake in Hims & Hers Health by 235.8% during the fourth quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock valued at $29,000 after purchasing an additional 632 shares in the last quarter. Geneos Wealth Management Inc. bought a new stake in shares of Hims & Hers Health in the 1st quarter worth about $30,000. Finally, Greenline Wealth Management LLC bought a new stake in shares of Hims & Hers Health in the 4th quarter worth about $36,000. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.